PURPOSE: The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor–positive [ER+], human epidermal growth factor receptor 2–negative [HER2–]) as Basal-Type. We report the association of 80-GS reclassification with neoadjuvant treatment response and 5-year outcome in patients with breast cancer. METHODS: Neoadjuvant Breast Registry Symphony Trial (NBRST; NCT01479101 ) is an observational, prospective study that included 1,069 patients with early-stage breast cancer age 18-90 years who received neoadjuvant therapy. Pathologic complete response (pCR) and 5-year distant metastasis-free survival (DMFS) and overall survival (OS) were assessed in 477 patients with IHC-defined ER+, HER2– tumors and in a reference group of 229 patients with IHC-defined triple-negative breast cancer (TNBC). RESULTS: 80-GS reclassified 15% of ER+, HER2– tumors (n = 73) as Basal-Type (ER+/Basal), which had similar pCR compared with TNBC/Basal tumors (34% v 38%; P = .52), and significantly higher pCR than ER+/Luminal A (2%; P < .001) and ER+/Luminal B (6%; P < .001) tumors. The 5-year DMFS (%, [95% CI]) was significantly lower for patients with ER+/Basal tumors (66% [52.6 to 77.3]), compared with those with ER+/Luminal A tumors (92.3% [85.2 to 96.1]) and ER+/Luminal B tumors (73.5% [44.5 to 79.3]). Importantly, patients with ER+/Basal or TNBC/Basal tumors that had a pCR exhibited significantly improved DMFS and OS compared with those with residual disease. By contrast, patients with ER+/Luminal B tumors had comparable 5-year DMFS and OS whether or not they achieved pCR. CONCLUSION: Significant differences in chemosensitivity and 5-year outcome suggest patients with ER+/Basal molecular subtype may benefit from neoadjuvant regimens optimized for patients with TNBC/Basal tumors compared with patients with ER+/Luminal subtype. These data highlight the importance of identifying this subset of patients to improve treatment planning and long-term survival.
1 November 1995 in Molecular Reproduction and Development
PURPOSE: The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete response (pCR) and 5-year outcomes in patients with early-stage breast cancer. METHODS: Standard-of-care neoadjuvant chemotherapy combined with trastuzumab or trastuzumab plus pertuzumab was given to patients with human epidermal growth factor receptor 2 (HER2)–positive tumors (n = 295). pCR was the primary end point, with secondary end points of distant metastasis-free survival and overall survival at 5 years. RESULTS: Among clinically defined HER2-positive (cHER2) tumors, the 80-gene assay identified 29.5% (87 of 295) as Luminal-Type (cHER2/gLuminal), 14.9% (44 of 295) as Basal-Type (cHER2/gBasal), and 55.6% (164 of 295) as HER2-Type (cHER2/genomically classified as HER2 [gHER2]). Patients with cHER2/gHER2 tumors had a higher pCR rate (61.6%) compared with non-gHER2 tumors (26.7%; P < .001). Dual targeting for cHER2/gHER2 tumors yielded a higher pCR rate (75%) compared with those treated with single HER2-targeted therapy (54%; P = .006). For cHER2/gBasal tumors, the 42.9% pCR rate observed with dual targeting was not different from that with trastuzumab alone (46.4%; P = .830). Among those with cHER2/gBasal tumors, 5-year distant metastasis-free survival (68.6%; 95% CI, 49.1 to 81.9) was significantly worse than in patients with cHER2/gLuminal tumors (88.9%; 95% CI, 78.0 to 94.6) and cHER2/gHER2 tumors (87.4%; 95% CI, 80.2 to 92.2; P = .010), with similar corresponding overall survival differences. CONCLUSION: The 80-gene assay identified meaningful genomic diversity in patients with cHER2 disease. Patients with cHER2/gHER2 tumors, who benefitted most from dual HER2-targeted therapy, accounted for approximately half of the cHER2 cohort. Genomically Luminal tumors had low pCR rates but good 5-year outcomes. cHER2/gBasal tumors derived no benefit from dual therapy and had significantly worse 5-year prognosis; these patients merit special consideration in future trials.
1 January 2015 in International Journal of Surgery Case Reports
INTRODUCTION: Pseudoangiomatous stromal hyperplasia (PASH) is a benign tumor of the breast that can achieve large, or even giant, dimensions. Resection of giant tumors can pose cosmetic challenges. CASE PRESENTATION: We report the prospective cosmetic outcome of a 31-year old female with a 21-cm PASH tumor of the right breast using simple excision through an inframammary approach. The patient was followed for 6 months before final cosmesis was established. Breast cosmesis was considered very good by both patient and physician. Mild external rotation of the nipple and mild contour changes involving the lateral aspect of the breast persisted at 6 months. DISCUSSION: Avoidance of more complex alternatives such as reduction mammoplasty and/or mastopexy was achieved by allowing the skin envelope to undergo natural involution over a period of six months. CONCLUSION: Inframammary simple excision of a giant PASH tumor is appropriate in select patients.
Introduction: Margin status after lumpectomy is crucial in determining risk of local recurrence. Current guidelines recommend “no ink on tumor” as adequate negative margins for invasive breast carcinoma. Still, up to 20% of patients may have positive margins and need re-excision. This study explored the use of a commercially available tumor marking system during specimen radiography and its effect on re-excision rates in breast conservation surgery. Methods: With IRRB approval, a review was conducted of a prospectively collected cohort of 105 study patients and a retrospectively collected cohort of 92 control patients with invasive breast carcinoma undergoing breast conservation surgery. In the study group, lumpectomy specimens were labeled with clips from a commercial tumor marking system, followed by two-view radiography to assess the need for shave margins. The surgeon interpreted the radiograph, and, at their discretion, excised additional margins. A control group was managed by the same surgeons without the tumor marking system. Categorical variables were compared using Chi-Squared or Fisher’s exact tests and continuous variables were compared using t-tests or Wilcoxon Rank Sum tests depending on their distribution. Results: A total of 197 patients were divided into a study group (n = 105) and a control group (n = 92). The types of margin excision rates differed significantly between groups ( P ≤ 0.0105). In the study group, the rates of selective and complete margin excisions were 39% and 7%, respectively, while 53% had no margins excised, as determined using the tumor marking system. In the control group, rates of selective and complete margin excisions were 42% and 21%, respectively, and 37% had no margins excised. Final pathology showed positive margins in 24% (study) vs 21% (control), with no significant difference between the groups ( P ≤ 0.0810). Conclusions: The tumor marking system did not decrease the rate of margin positivity compared to the control group. However, the study group demonstrated a significant decrease in the number of patients requiring selective or complete margin excision.
Introduction: Radiation therapy after breast‐conserving surgery reduces local recurrence and improves survival. The new standard set forth by the Commission on Cancer (CoC) requires that radiation be initiated in less than or equal to 60 days of definitive surgery for patients receiving breast‐conserving surgery for Stages I–III breast cancer who do not undergo adjuvant chemo or immunotherapy. Timely access to radiation is critical, and yet there still exists a modest number of patients who experience delays in the initiation of radiation. We aim to highlight this disparity at our institution and identify the socioeconomic factors that contribute to it. Methods: Using the Breast Cancer Registry, we conducted a retrospective analysis of women diagnosed with Stages I–III breast cancer, who underwent breast‐conserving surgery between 2011 and 2021. Women who received chemotherapy were excluded. We stratified patients based on socioeconomic and other factors and examined which factors attributed to an increased interval from surgery to initiation of radiation greater than the current standard of 60 days. Results: A cohort of 427 women meeting the inclusion criteria was identified. Most patients received adjuvant radiation within the new standard of 60 days from definitive surgery (72.4%). However, patients of White race were significantly more likely to receive adjuvant radiation within 60 days of final surgery (74.7%) compared to patients of Black race (55.6%). In addition, patients with private insurance or Medicare were more likely to receive adjuvant radiation within the current set standard (74.9% and 74.5%, respectively) in comparison to patients with Medicaid (50.0%). Conclusion: This analysis identifies disparities in breast cancer treatment among minority populations at our institution. It also suggests that insurance status can affect the receipt of treatment in a recommended time frame. There is research that shows a delay in radiation impairs survival. These results indicate that improving access to timely adjuvant radiation may be leveraged to lessen disparities experienced by minority races regardless of insurance status.